The guideline provides recommendations for best practice in the screening, surveillance, diagnosis, assessment and clinical interventions for children and young people with ASD.
This guideline provides advice at all stages of the patient’s pathway of care, from primary prevention to early recognition, treatment and follow up. It does not address melanomas of non-cutaneous origin...
This guideline provides evidence-based recommendations and best practice guidance on the management of patients with chronic heart failure.
This guideline provides recommendations for the management of patients with ACS within the first 12 hours and up to hospital discharge.
EANO–ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours
These EANO-ESMO joint recommendations for the diagnosis and treatment of leptomeningeal metastasis from solid cancers represent the first European guideline initiative on this topic.
Most anticancer treatments carry a risk for infusion reactions which incidence may increase when different agents are administered concomitantly.
Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Immunotherapy is an essential component of cancer care and expands the treatment possibilities for patients. Immune checkpoint inhibitors are among the most promising drugs but are associated with toxicities.
Methylmalonic and propionic acidemia (MMA/PA) are inborn errors of metabolism characterized by accumulation of propionic acid and/or methylmalonic acid due to deficiency of methylmalonyl -CoA mutase (MUT) or propionyl-CoA carboxylase (PCC).
Urea cycle disorders (UCDs) are inborn errors of ammonia detoxification/arginine synthesis due to defects affecting the catalysts of the Krebs-Henseleit cycle...
Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation.
Non-vitamin K antagonist oral anticoagulants (NOACs) are an alternative for vitamin K antagonists (VKAs) to prevent stroke in patients with non-valvular atrial fibrillation (AF).